| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
N-Acetyl-d-mannosamine (also known as N-Acetyl-D-mannosamine; ManNAc; DEX M-74) is a compound that has the potential for the treatment of neural disorders such as hereditary inclusion body myopathyan. It is also an essential precursor of N-acetylneuraminic acid (NeuAc), the specific monomer of bacterial capsular polysialic acid (PA). N-Acetyl-D-mannosamine (ManNAc) can be metabolized by GNE and GlcNAc 2-epimerase (Renin binding protein, RnBP), into ManNAc-6-phosphate and GlcNAc, respectively. N-Acetyl-d-mannosamine (ManNAc) and its derivatives activates hypocretin (HCRT) gene expression in the orexin neurons, providing a potential model for the testing of a therapy for neural disorders.
| Targets |
Human Endogenous Metabolite
|
|---|---|
| References |
|
| Molecular Formula |
C8H15NO6
|
|---|---|
| Molecular Weight |
221.2078
|
| Exact Mass |
221.09
|
| Elemental Analysis |
C, 40.17; H, 7.16; N, 5.86; O, 46.82
|
| CAS # |
3615-17-6
|
| Related CAS # |
Cyclic N-Acetyl-D-mannosamine;7772-94-3;N-Acetyl-D-mannosamine-13C;N-Acetyl-D-mannosamine-13C-1;N-Acetyl-D-mannosamine-15N
|
| Appearance |
Solid powder
|
| SMILES |
CC(N[C@@H]([C@@H](O)[C@H](O)[C@H](O)CO)C=O)=O.[H]O[H]
|
| InChi Key |
KVWIBLJBIFTKIZ-XNJRRJNCSA-N
|
| InChi Code |
InChI=1S/C8H15NO6.H2O/c1-4(12)9-5(2-10)7(14)8(15)6(13)3-11;/h2,5-8,11,13-15H,3H2,1H3,(H,9,12);1H2/t5-,6-,7-,8-;/m1./s1
|
| Chemical Name |
N-((2S,3R,4S,5R)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl)acetamide hydrate
|
| Synonyms |
N-Acetyl-D-mannosamine (ManNAc); DEX-M-74; DEX M-74; DEXM74; DEX M 74; ManNAc;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~565.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (113.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5206 mL | 22.6030 mL | 45.2059 mL | |
| 5 mM | 0.9041 mL | 4.5206 mL | 9.0412 mL | |
| 10 mM | 0.4521 mL | 2.2603 mL | 4.5206 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
